Modality
mRNA
MOA
TROP-2 ADC
Target
PD-L1
Pathway
Proteasome
FLAtopic DermEoE
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
~Nov 2020
→ ~Feb 2022
NDA/BLA
May 2022
→ Jan 2030
NDA/BLACurrent
NCT08232161
959 pts·FL
2022-05→2030-01·Not yet recruiting
959 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-063.8y awayPh3 Readout· FL
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2030-01-06 · 3.8y away
FL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08232161 | NDA/BLA | FL | Not yet recr... | 959 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 |